GSA CAPITAL PARTNERS LLP

Position in AVXL — Anavex Life Sciences Corp.

CIK 1362033 LONDON, X0

Position in AVXL

as of Mar 31, 2026 · filed May 8, 2026 Compact

Position Value

$133,382

-$421,547 QoQ

Shares Held

43,447

-72.1% QoQ

Ownership

0.047%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Sep 2020

12 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Mar 31, 2026

GSA CAPITAL PARTNERS LLP holds $101,563,069 across 163 Biotechnology names. AVXL ranks #137 (0.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	REGN	Regeneron Pharmaceuticals, Inc.	3,831	$2,959,983
2	ARDX	Ardelyx, Inc.	473,061	$2,833,635
3	NTLA	Intellia Therapeutics, Inc.	178,301	$2,285,818
4	NUVB	Nuvation Bio Inc.	495,792	$2,126,947
5	RXRX	Recursion Pharmaceuticals, Inc.	669,568	$2,055,573
6	WVE	Wave Life Sciences Ltd.	282,719	$2,049,712
7	SRPT	Sarepta Therapeutics, Inc.	90,960	$1,979,289
8	IOVA	Iovance Biotherapeutics, Inc.	557,085	$1,955,368

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$133,382	43,447	-72.1%	Shares	Sole	2026-05-08
2025-12-31	$554,929	155,879	+147.1%	Shares	Sole	2026-02-06
2025-09-30	$561,412	63,080	+127.9%	Shares	Sole	2025-11-07
2025-03-31	$237,528	27,684	-69.0%	Shares	Sole	2025-05-08
2024-09-30	$507,218	89,299	-59.6%	Shares	Sole	2024-11-05
2024-06-30	$932,029	220,860	+957.0%	Shares	Sole	2024-08-15
2024-03-31	$106,355	20,895	-52.7%	Shares	Sole	2024-05-03
2023-06-30	$358,850	44,139	+45.7%	Shares	Sole	2023-08-14
2021-09-30	$543,902	30,301	+78.2%	Shares	Sole	2021-11-12
2021-06-30	$388,688	17,003	-65.8%	Shares	Sole	2021-08-05
2020-12-31	$268,261	49,678	+68.5%	Shares	Sole	2021-02-03
2020-09-30	$134,152	29,484	—	Shares	Sole	2020-11-06
No filing history on record for this holder in this stock.